Breast Cancer Awareness Month

Sara M. Tolaney, MD, MPH, an expert breast oncologist, reviews the overall treatment landscape for breast cancer.

Expert insights on biomarker testing in breast cancer, with a focus on key markers associated with specific subtypes.

Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.

A comprehensive overview of the treatment landscape in early-stage breast cancer, with a focus on CDK4/6 and PARP inhibitors.

A medical oncologist offers clinical insights on the evolving treatment landscape for patients with HER2+ breast cancer.

Sara M. Tolaney, MD, MPH, reviews key clinical trial data recently updated in the metastatic HER2+ breast cancer treatment space.

Expert perspectives on the treatment landscape for triple-negative breast cancer and the evolving role of immunotherapy in this space.

A breast oncologist looks to the future of breast cancer treatment and discusses emerging therapies and ongoing clinical trials.

Sara M. Tolaney, MD, MPH, concludes the program with advice for community oncologists who are treating patients with breast cancer.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Patients with breast cancer harboring BRCA1/2 mutations appear to be more likely to undergo mastectomies than those without, according to Zachary Kiss, DO.